This company listing is no longer active
Genor Biopharma Holdings Past Earnings Performance
Past criteria checks 0/6
Key information
-19.0%
Earnings growth rate
-7.6%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | -55.0% |
Return on equity | -41.0% |
Net Margin | -29,430.4% |
Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genor Biopharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 22 | 3 | -870 | 309 | 636 |
31 Mar 22 | 1 | -868 | 307 | 625 |
31 Dec 21 | 0 | -865 | 306 | 613 |
30 Sep 21 | 3 | -1,880 | 299 | 617 |
30 Jun 21 | 7 | -2,895 | 292 | 620 |
31 Mar 21 | 10 | -3,086 | 281 | 721 |
31 Dec 20 | 10 | -3,027 | 241 | 697 |
31 Mar 20 | 12 | -590 | 116 | 480 |
31 Dec 19 | 13 | -522 | 89 | 439 |
31 Dec 18 | 7 | -288 | 22 | 271 |
Quality Earnings: 6998 is currently unprofitable.
Growing Profit Margin: 6998 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6998 is unprofitable, and losses have increased over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare 6998's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6998 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: 6998 has a negative Return on Equity (-40.98%), as it is currently unprofitable.